These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Subungual abscess: a new ungual side-effect related to docetaxel therapy. Vanhooteghem O; Richert B; Vindevoghel A; Vandenbossche L; Vandeveire A; de la Brassinne M Br J Dermatol; 2000 Aug; 143(2):462-4. PubMed ID: 10951175 [No Abstract] [Full Text] [Related]
6. Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Llombart-Cussac A; Pivot X; Spielmann M Arch Dermatol; 1997 Nov; 133(11):1466-7. PubMed ID: 9371043 [No Abstract] [Full Text] [Related]
7. Docetaxel-related skin, nail, and vascular toxicity. Leonard GD; Zujewski JA Ann Pharmacother; 2003 Jan; 37(1):148. PubMed ID: 12564432 [No Abstract] [Full Text] [Related]
8. [Yellow nails]. Auvinet M; Dahan S; Dingremont C; Ollier S; Juchet H; Arlet P Rev Med Interne; 1998 May; 19(5):353-4. PubMed ID: 9775172 [No Abstract] [Full Text] [Related]
9. Docetaxel (Taxotere) for advanced breast cancer. Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520 [No Abstract] [Full Text] [Related]
10. Nail toxicity related to taxanes. Mourad YA; Matta-Muallem M; Shamseddine A Dermatol Online J; 2003 Aug; 9(3):15. PubMed ID: 12952762 [TBL] [Abstract][Full Text] [Related]
11. Nail changes due to docetaxel. Pavithran K; Doval DC Br J Dermatol; 2002 Apr; 146(4):709-10. PubMed ID: 11966714 [No Abstract] [Full Text] [Related]
12. Docetaxel-induced nail dystrophy. Nicolopoulos J; Howard A Australas J Dermatol; 2002 Nov; 43(4):293-6. PubMed ID: 12423438 [TBL] [Abstract][Full Text] [Related]
13. Docetaxel. Leahy M; Howell A Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374 [TBL] [Abstract][Full Text] [Related]
14. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959 [TBL] [Abstract][Full Text] [Related]
15. [Current developments in use of docetaxel (taxotere) in gynecologic oncology]. Jackisch C Med Klin (Munich); 1998 Sep; 93 Suppl 3():4-15. PubMed ID: 9796219 [No Abstract] [Full Text] [Related]
16. Docetaxel. A review of its role in breast cancer treatment. Antoine EC; Rixe O; Auclerc G; Weil M; Khayat D Am J Clin Oncol; 1997 Aug; 20(4):429-32. PubMed ID: 9256905 [No Abstract] [Full Text] [Related]
17. Onycholysis in patients treated with docetaxel. Obermair A; Binder M; Barrada M; Bancher-Todesca D; Asseryanis E; Kubista E Ann Oncol; 1998 Feb; 9(2):230-1. PubMed ID: 9553674 [No Abstract] [Full Text] [Related]
18. Nail bed dyschromia secondary to docetaxel therapy. Jacob CI; Patten SF Arch Dermatol; 1998 Sep; 134(9):1167-8. PubMed ID: 9762045 [No Abstract] [Full Text] [Related]
19. Paclitaxel and docetaxel in breast and ovarian cancer. Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. Roh MR; Cho JY; Lew W Yonsei Med J; 2007 Feb; 48(1):124-6. PubMed ID: 17326255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]